Scleroderma Clinical Trials
Here are the 6 most popular medical studies for
Efzofitimod for Scleroderma-Related Lung Disease
This trial will evaluate the safety and effectiveness of an experimental drug to treat SSc-ILD, with 25 participants receiving either the drug, placebo, or a different dose of the drug. Results will measure changes in skin and ILD.
Behavioural Intervention
Online Fatigue Management for Scleroderma
This trial is testing whether an online fatigue management program can help reduce fatigue, pain, and increase confidence in managing fatigue and daily activities. It involves completing surveys before and after the intervention, and attending and participating in 1.5 hour weekly videoconference meetings for 6 weeks.
Popular filter options for trials
SSc Clinical Trials
View 32 SSc medical studies.
Monoclonal Antibodies
Brentuximab Vedotin for Systemic Sclerosis
This trial aims to test the safety and effectiveness of Brentuximab vedotin in patients with a certain type of skin disease called diffuse cutaneous systemic sclerosis who have not responded well to previous treatment
Skin involvement for Systemic Sclerosis
Systemic Sclerosis (SSc) is an autoimmune connective tissue disease characterized by autoantibodies, fibrosis and microvascular injury and endothelial cell activation that results in vascular damage. Vascular injury induces both innate and acquired immune responses resulting in fibroblast activation and organ fibrosis. SSc may target multiple organs, including: skin, lungs, heart, vascularization, kidneys, the gastrointestinal tract and musculoskeletal structures. Mortality among scleroderma patients is significant, with a 3.5 standardized mortality ratio (SMR) in studies of prevalent cases. This mortality may be increased in the early years of the disease, reaching a SMR of 4 in a multinational inception cohort. In general, treatment strategies target involved organs as early as possible to avoid damage. Many treatment options are available for each manifestation, but evidence with respect to the order of treatment is scarce. Financial costs, the lack of proper outcome measures, difficulty to recruit patients as a rare disease, all prevent the development of new big clinical trials, oppositely to other common diseases such as stroke or cancer. The heterogeneous features of SSc may make trials challenging. The current guidelines available are the British guidelines (2017) , and the updated European League Against Rheumatism (EULAR) guidelines, published in 2017. Management guidelines have some gaps regarding second-line treatment, combinations and there are no proposed algorithms. With the pragmatic trials, the investigators intend to fill the gap between the complicated randomized clinical trials and the observational studies. Using the treatments that have already been proved useful in SSc, in an open-label randomized way and based on some refined expert-made algorithms, will allow the investigators to establish the order in how to use them. Patients will be offered to participate with the collection of their clinical data and, if they give their consent, they will be randomized according to the algorithms. There will be an optional part of the study consisting in the collection of blood samples and skin samples for future research.
Thromboxane A2 Receptor Antagonist
Oral Ifetroban for Scleroderma
This trial will test ifetroban, a new drug, to see if it is safe and effective for treating scleroderma, a disease that causes the hardening and tightening of skin, or scleroderma-associated pulmonary arterial hypertension.
Systemic Scleroderma Clinical Trials
View 10 Systemic Scleroderma medical studies.
Skin involvement for Systemic Sclerosis
Systemic Sclerosis (SSc) is an autoimmune connective tissue disease characterized by autoantibodies, fibrosis and microvascular injury and endothelial cell activation that results in vascular damage. Vascular injury induces both innate and acquired immune responses resulting in fibroblast activation and organ fibrosis. SSc may target multiple organs, including: skin, lungs, heart, vascularization, kidneys, the gastrointestinal tract and musculoskeletal structures. Mortality among scleroderma patients is significant, with a 3.5 standardized mortality ratio (SMR) in studies of prevalent cases. This mortality may be increased in the early years of the disease, reaching a SMR of 4 in a multinational inception cohort. In general, treatment strategies target involved organs as early as possible to avoid damage. Many treatment options are available for each manifestation, but evidence with respect to the order of treatment is scarce. Financial costs, the lack of proper outcome measures, difficulty to recruit patients as a rare disease, all prevent the development of new big clinical trials, oppositely to other common diseases such as stroke or cancer. The heterogeneous features of SSc may make trials challenging. The current guidelines available are the British guidelines (2017) , and the updated European League Against Rheumatism (EULAR) guidelines, published in 2017. Management guidelines have some gaps regarding second-line treatment, combinations and there are no proposed algorithms. With the pragmatic trials, the investigators intend to fill the gap between the complicated randomized clinical trials and the observational studies. Using the treatments that have already been proved useful in SSc, in an open-label randomized way and based on some refined expert-made algorithms, will allow the investigators to establish the order in how to use them. Patients will be offered to participate with the collection of their clinical data and, if they give their consent, they will be randomized according to the algorithms. There will be an optional part of the study consisting in the collection of blood samples and skin samples for future research.
Thromboxane A2 Receptor Antagonist
Oral Ifetroban for Scleroderma
This trial will test ifetroban, a new drug, to see if it is safe and effective for treating scleroderma, a disease that causes the hardening and tightening of skin, or scleroderma-associated pulmonary arterial hypertension.
Alkylating agents
TBI + Cyclophosphamide and Stem Cell Transplant for Scleroderma
This trial is testing the side effects and feasibility of a new way to give total body radiation therapy (IMRT) with the chemotherapy drug cyclophosphamide before stem cell transplant to treat severe systemic sclerosis.
Scleroderma Clinical Trials With No Placebo
View 41 scleroderma medical studies that do not have a placebo group.
Monoclonal Antibodies
Brentuximab Vedotin for Systemic Sclerosis
This trial aims to test the safety and effectiveness of Brentuximab vedotin in patients with a certain type of skin disease called diffuse cutaneous systemic sclerosis who have not responded well to previous treatment
Skin involvement for Systemic Sclerosis
Systemic Sclerosis (SSc) is an autoimmune connective tissue disease characterized by autoantibodies, fibrosis and microvascular injury and endothelial cell activation that results in vascular damage. Vascular injury induces both innate and acquired immune responses resulting in fibroblast activation and organ fibrosis. SSc may target multiple organs, including: skin, lungs, heart, vascularization, kidneys, the gastrointestinal tract and musculoskeletal structures. Mortality among scleroderma patients is significant, with a 3.5 standardized mortality ratio (SMR) in studies of prevalent cases. This mortality may be increased in the early years of the disease, reaching a SMR of 4 in a multinational inception cohort. In general, treatment strategies target involved organs as early as possible to avoid damage. Many treatment options are available for each manifestation, but evidence with respect to the order of treatment is scarce. Financial costs, the lack of proper outcome measures, difficulty to recruit patients as a rare disease, all prevent the development of new big clinical trials, oppositely to other common diseases such as stroke or cancer. The heterogeneous features of SSc may make trials challenging. The current guidelines available are the British guidelines (2017) , and the updated European League Against Rheumatism (EULAR) guidelines, published in 2017. Management guidelines have some gaps regarding second-line treatment, combinations and there are no proposed algorithms. With the pragmatic trials, the investigators intend to fill the gap between the complicated randomized clinical trials and the observational studies. Using the treatments that have already been proved useful in SSc, in an open-label randomized way and based on some refined expert-made algorithms, will allow the investigators to establish the order in how to use them. Patients will be offered to participate with the collection of their clinical data and, if they give their consent, they will be randomized according to the algorithms. There will be an optional part of the study consisting in the collection of blood samples and skin samples for future research.
View More Trials
See another 21 medical studies focused on .
Frequently Asked Questions
Introduction to
What are the top hospitals conducting undefined research?
The quest for medical advancements and improved treatments is an ongoing journey, extending beyond specific conditions to encompass a wide range of health concerns. In this pursuit, several top hospitals are leading the way in clinical trials for undefined conditions. Massachusetts General Hospital in Boston stands out with four active trials focused on these elusive ailments. Known for their commitment to innovative research, this hospital's dedication shines through as they strive to unravel the mysteries surrounding unidentified diseases.
On the West Coast, Pacific Arthritis Care Center brings its expertise to bear on these enigmatic conditions as well. Located in Los Angeles, this center conducts four active clinical trials aimed at shedding light on undefined illnesses that continue to challenge the medical community.
Heading further east, Johns Hopkins University in Baltimore has also devoted significant resources toward understanding and treating unknown disorders. With three ongoing clinical trials dedicated to undefined conditions, this renowned institution showcases its commitment to pushing boundaries and seeking answers where there are none.
In Houston, The University of Texas Health Science Center is making substantial contributions by conducting two active clinical trials related to undisclosed diseases. Through rigorous scientific investigation and collaboration with experts from various fields, they aim to make significant breakthroughs that can positively impact patients' lives.
Across the Atlantic Ocean lies St. Joseph's Health Care Rheumatology Clinic in London—a notable player when it comes to tackling poorly understood illnesses head-on. This clinic actively engages in two mysterious condition-focused clinical trials while providing hope and support for patients grappling with unidentified health challenges.
As we navigate through uncharted territories within healthcare, these leading hospitals serve as beacons of progress—channeling their knowledge and expertise into finding solutions even when faced with uncertainty. The determination of researchers within these institutions reinforces their unwavering commitment towards uncovering answers that will ultimately improve countless lives impacted by undetermined conditions worldwide
Which are the best cities for undefined clinical trials?
When it comes to undefined clinical trials, several cities emerge as prominent hubs for research. Los Angeles, California leads the way with 16 ongoing trials investigating treatments like MK-2225, HZN-825 QD, and MT-7117. Houston, Texas follows closely behind with 10 active trials focusing on interventions such as Peripheral Blood Stem Cell Transplantation and Transcutaneous Electrical Acustimulation (TEA). Additionally, Boston Massachusetts and Baltimore Maryland both offer opportunities for participation in 10 and 8 studies respectively. Finally, Cleveland Ohio presents promising options with its 7 current trials exploring treatments like TEPEZZA and efzofitimod 450 mg. These cities serve as important centers for cutting-edge research that contributes to the advancement of medical knowledge and potential breakthroughs in healthcare.
Which are the top treatments for undefined being explored in clinical trials?
Currently, there are several top treatments for undefined conditions being investigated in clinical trials. These include:
- Daratumumab: Being tested in six active trials and has a total of 134 breast cancer trials since 2012.
- Belantamab mafodotin: Under examination in four ongoing trials with a history of 26 breast cancer trials since its introduction in 2018.
- Lenalidomide: Engaged in three active breast cancer studies and has been part of 280 clinical trials across various conditions since its debut in 2003.
With each trial, researchers come closer to uncovering potential breakthroughs that may benefit patients facing undefined health challenges.
What are the most recent clinical trials for undefined?
Several exciting clinical trials have recently emerged, offering potential breakthroughs in the realm of undefined conditions. One promising study focuses on efzofitimod 450 mg, a Phase 2 trial that became available on September 1st, 2023. Additionally, Mycophenolate mofetil is being investigated as a treatment option through another Phase 2 trial for this condition. A Phase 3 trial involving Anifrolumab administered subcutaneously on a weekly basis also holds promise for patients with undefined conditions and became available on July 13th, 2023. These trials aim to provide valuable insights into potential treatments and improve patient outcomes in the face of this enigmatic ailment.
What undefined clinical trials were recently completed?
I apologize, but I cannot provide a specific answer to the question as it asks for "undefined" clinical trials. Could you please provide more information or specify which clinical trials you are referring to? That way, I can offer a clear and accurate response tailored to your query.